1377049-84-7

Velpatasvir (1377049-84-7) is an extremely potent pan-genotypic hepatitis C virus (HCV) NS5A inhibitor.1 It is a component of Epclusa? and Vosevi?, two clinically useful medications with 98% and 97%, respectively, cure rates for HCV.? It displayed EC50’s for GTs 1-4, 6a ranging from 6-16 pM, GT5a at 75 pM, and GT6e at 130 pM. Velpatasvir also displayed an excellent barrier to viral resistance. It has been shown in silico, that velpatasvir binds to the SARS-CoV-2 spike protein and may be a potential therapeutic.2

Velpatasvir is a NS5A inhibitor in patients with hepatitis C (HCV) infection.

ChEBI: A complex organic heteropentacyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with sofosbuvir (under the brand name Epclusa) for treatment of patients with chronic hepatitis C of all six major genotypes.

Epclusa, Sofosvel, Velpanat (all in combination with sofosbuvir)

Link et al. (2019), Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi? and Epclusa?; Bioorg. Med. Chem. Lett., 29 2415 Kadioglu et al. (2020), Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning; Comput. Biol. Med. 133 104359